Abstract P5-02-03: Combined Biomarker Analysis for Prediction of Pathological Complete Response (pcr) after 12 Weeks of Pembrolizumab + Trastuzumab + Pertuzumab in HER2-enriched Early Breast Cancer: Keyriched-1 TrialMonika Graeser,Sherko Kuemmel,Oleg Gluz,Friedrich Feuerhake,Valery Volk,Daniel Ulbrich-Gebauer,Claudia Biehl,Mattea Reinisch,Athina Kostara,Iris Scheffen,Kerstin Luedtke-Heckenkamp,Andreas Hartkopf,Felix Hilpert,Angela Kentsch,Carsten Ziske,Reinhard Depenbusch,Michael Braun,Jens-Uwe Blohmer,Christine zu Eulenburg,Matthias Christgen,Ronald Kates,Stephan Bartels,Hans-Heinrich Kreipe,Enrico Pelz,Peter Schmid,Nadia HarbeckCancer Research（2023）引用 0|浏览57AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
